What is CBG? Cannabigerol and current research

Author: Dipl.-Chem. Mohammad Reza Talebnasab
Editorially updated: 12 October 2026

Cannabigerol, or CBG, is a cannabinoid found in the cannabis plant. Alongside the better-known compounds CBD and THC, it is attracting increasing scientific attention. Searches for CBG's effects often return far-reaching claims. It is more informative to consider plant biology, laboratory research and the human studies conducted so far separately.

CBG and CBGA: an important distinction

CBG is often called the ‘mother of all cannabinoids’. More precisely, however, cannabigerol must be distinguished from its acid form, cannabigerolic acid, or CBGA. In the plant, CBGA is a starting material for the enzymatic formation of various cannabinoid acids, including CBDA and THCA. Decarboxylation can convert CBGA into neutral CBG. CBG and CBGA are therefore not interchangeable names. Study of cannabinoid biosynthesis · Experimental study of decarboxylation

These plant-chemical relationships do not mean that CBG taken into the human body is automatically converted into CBD or THC. Describing a precursor in the plant does not describe a medical effect.

CBG's effects: what is being studied scientifically?

CBG research investigates biological signalling pathways, inflammatory processes and nervous-system functions, among other subjects. What can be concluded depends on how the research was conducted: an effect in isolated cells, a finding in an animal model and a clinical study result answer different questions. They must not be treated as equivalent evidence of a health benefit.

Our page on the endocannabinoid system explains the principles of the body's own cannabinoids and their receptors. CBG is not equivalent to the body's signalling molecules anandamide and 2-AG.

Have there been CBG studies in humans?

Yes. A placebo-controlled crossover study published in 2024 investigated a single CBG administration in 34 healthy adults. Participants completed two sessions, receiving CBG or placebo. Findings with CBG included lower self-reported anxiety; some other results depended on the time point. The study did not investigate long-term treatment or a patient group with a diagnosed anxiety disorder. Cuttler et al., 2024

The small sample, short observation period and conflicts of interest disclosed in the article limit generalisability. The study provides an early signal for further research, not a basis for guaranteed relaxation, improved mood or a treatment recommendation.

Another randomised, placebo-controlled study involving 63 US veterans investigated CBG over four weeks of treatment. Sleep ratings improved in both groups, without a statistically significant difference between CBG and placebo. No statistically established benefit was found for the quality-of-life measures either. The small sample, protocol deviations and frequent additional cannabis use limit the strength of the findings. Emerson et al., online 2025 / issue 2026

A laboratory study published in 2026 investigated the short-term effects and blood concentrations of oral CBG in twelve healthy adults. CBG was generally well tolerated under the conditions studied; no marked pharmacodynamic effects were observed. However, this small single-dose investigation establishes neither therapeutic efficacy nor long-term safety. Wolinsky et al., 2026

Inflammation, the nervous system and tumour biology

CBG was investigated in a mouse model of experimentally induced intestinal inflammation. Other experiments examined mouse models of Huntington's disease, colorectal cancer cells and animal models. These studies illustrate the biological questions researchers are exploring. They do not establish that CBG effectively treats Crohn's disease, Huntington's disease or cancer in humans. Intestinal inflammation model, 2013 · Huntington's disease models, 2015 · Preclinical cancer research, 2014

Nor can a general recommendation for glaucoma, chronic pain or depression be inferred from the investigations described here. Results for other cannabinoids or combination preparations do not automatically establish CBG's efficacy.

CBG: adverse effects and unresolved safety questions

The limited human research to date does not allow a comprehensive assessment of long-term safety. The absence of particular adverse effects in a small, short study does not rule out rare risks or interactions. Specific populations, different compositions and longer-term use require their own investigations.

If you take medicines, have an existing condition or have other medical questions, individual assessment by a doctor or pharmacist is important. This article provides no basis for self-treatment or stopping prescribed medicines.

Comparing CBG, CBD and CBN objectively

CBG, CBD and CBN are different compounds. Comparisons should consider their composition and the evidence available for each, rather than merely similar advertising terms. Further information is available on cannabidiol (CBD) and cannabinol (CBN).

For a product described as CBG oil, distinguish between its specific cannabinoid composition, concentration, carrier oil and a traceable analytical report. Evidence of what a product contains is not evidence of medical efficacy. The history of cannabis explains the historical background.

Further reading: Cannabinoids and medicines: mechanisms and risks of interactions.

Note: this article provides general scientific information. It does not replace diagnosis, medical advice or treatment and contains no dosage or product-use recommendations.

Product information: 10% CBG broad-spectrum distillate · Compare CBD–CBG sets.